• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote "FOR" Re-Election of Its Highly Qualified Directors

    5/20/24 1:04:29 PM ET
    $CWCO
    $SKYX
    $VVOS
    Water Supply
    Utilities
    Building Products
    Consumer Discretionary
    Get the next $CWCO alert in real time by email

    GEORGE TOWN, Cayman Islands, May 20, 2024 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, today issued the following statement commenting on the reports issued by Institutional Shareholder Services ("ISS") and Glass Lewis regarding the Company's May 28, 2024 Annual General Meeting of Shareholders:

    The Company strongly disagrees with the recommendations to withhold votes from Linda Beidler-D'Aguilar, Brian E. Butler and Leonard J. Sokolow for re-election to the Company's Board of Directors (the "Board"). For the reasons provided below, as well as those provided in the Company's definitive proxy statement filed on April 18, 2024 (the "Proxy Statement") with the Securities and Exchange Commission (the "SEC"), the Company urges shareholders to vote "FOR" each of the nominees for election, including Ms. Beidler-D'Aguilar, Mr. Butler and Mr. Sokolow.

    Linda Beidler-D'Aguilar

    The ISS and Glass Lewis recommendations against the re-election of Ms. Beidler-D'Aguilar are due to her attendance at less than 75% of the aggregate number of (a) the total number of meetings of the Board and (b) the total number of meetings of all committees of the Board on which she served (collectively, the "Aggregate Meetings") held during 2023. Despite not meeting the 75% threshold, Ms. Beidler-D'Aguilar attended 69% of the Aggregate Meetings. Importantly, one of the meetings that she missed was convened on only two days' notice, and she already had a previous commitment that could not be changed. Had she been able to attend that one meeting, she would have attended over 75% of the Aggregate Meetings held during 2023. Further, shareholders should know that Ms. Beidler-D'Aguilar has attended 87% of the Aggregate Meetings held from November 2018 to the date of this press release.

    Ms. Beidler-D'Aguilar has made a commitment to the Company to attend at least 75% of the Aggregated Meetings during 2024 and each following year. As evidence of that commitment, Ms. Beidler-D'Aguilar has attended 100% of the Aggregate Meetings held to date during 2024.

    The Board believes that it is important that Ms. Beidler-D'Aguilar be re-elected because of her more than 35 years of experience as an attorney; her legal, business and financial knowledge acquired during that period; and her knowledge of, and business contacts in, the Caribbean. Although Ms. Beidler-D'Aguilar has served on the Board for coming up on six years, she has been involved with the Company's operations in The Bahamas since 1994, resulting in over 30 years' experience, history and knowledge with the Company.

    Additionally, the Board believes that Ms. Beidler-D'Aguilar adds diversity of thought and experience to the Board. She also brings gender diversity to the Board, being the only director on the Board to identify as a female. This is particularly important in light of Nasdaq's diversity rule, which requires Nasdaq-listed companies, such as the Company, to disclose information about board diversity statistics and either include women and minority directors on their boards or disclose why they do not. The Board believes that the failure to re-elect Ms. Beidler-D'Aguilar will diminish the capability and effectiveness of the Board and negatively impact the Board's progress with respect to diversity and inclusion efforts.

    Brian E. Butler

    The Glass Lewis recommendation against Mr. Butler is due to their concerns relating to board refreshment and gender diversity coupled with Mr. Butler's position as Chair of the Company's Nominations and Corporate Governance Committee (the "NCG Committee"). While the Company and the NCG strongly support routine director evaluation and understand the perceived value of periodic board refreshment, they also believe that this must be balanced by the need for changes to board composition based on an analysis of skills and experience necessary for the Company, and must be viewed from the perspective of the results of the Company and value creation for shareholders, as opposed to relying solely on age or tenure. In the Company's view, and in light of the Company's business in a specialized field, a director's experience can be a valuable asset to shareholders because of the complex, critical issues that the Board faces.

    The Company believes that it is precisely because of, and not in spite of, the average director's tenure being 24 years, that the Company has been able to thrive these past several years where companies have faced unprecedented challenges on a global scale. Throughout this time, the Board and the Company's executive management collaborated closely to ensure the Company met its commitments to a broad range of stakeholders, including employees, customers, the communities in which the Company operates, suppliers, and of course the Company's shareholders. Amidst the challenges, the past fiscal year offered another year for quality financial performance, and the Company delivered positive results for its shareholders, including returning approximately $5.5 million to shareholders in the form of dividends and increasing the stock price by over 100%.

    Further, the Company and the NCG believe that the directors represent a wide range of backgrounds and expertise, with one director identifying as female and three directors identifying as "two or more races or ethnicities" under The NASDAQ Stock Market's diversity rules. This means that over 50% of the non-executive members of the Board identify as a female or other minority. The Company and the NCG believe that the diversity of backgrounds, experiences, perspectives, and skills of the directors contributes to the Board's effectiveness in managing risk and providing guidance that positions the Company for long-term success. Further, of the eight directors, seven are independent, including the Chairman of the Board, and the sole executive director is Frederick W. McTaggart, who is the Chair of the Company's Environmental and Social Governance Committee.

    The Company, the Board and the NCG are very satisfied with the composition of the Board and would be hesitant to make a change solely based upon age, tenure or diversity consideration.

    The Board believes that it is important that Mr. Butler be re-elected because of his over 50 years of experience as a property developer (over 45 of those years in the Caribbean); his business and financial knowledge acquired during that period; and his knowledge of, and business contacts in, the Cayman Islands. The Board believes that the failure to re-elect Mr. Butler based upon concerns relating to board refreshment and gender diversity would not only be unwarranted, but would diminish the capability and effectiveness of the Board.

    Leonard J. Sokolow

    The ISS recommendation against Mr. Sokolow is due to him serving as the chief executive officer of a public company and as a director of more than two additional public companies, including the Company. As of the date the Proxy Statement was filed with the SEC, in addition to serving as a director of the Company, Mr. Sokolow served as Co-Chief Executive Officer and a director of SKYX Platforms Corp. (NASDAQ:SKYX) and served as a director of Vivos Therapeutics, Inc. (NASDAQ:VVOS) and Agrify Corporation. However, since the filing of the Proxy Statement, Mr. Sokolow has resigned as a director of Agrify Corporation. Accordingly, as of the date hereof, Mr. Sokolow serves as the chief executive officer of a public company and as a director of only two other public companies, including the Company, and, thus, is within the acceptable ISS parameters of additional board directorship.

    The Board believes that it is important that Mr. Sokolow be re-elected because of his experience as a director and principal executive officer; his legal, accounting, auditing and consulting background; and his qualifications to serve as the Company's "audit committee financial expert." With his background in accounting, audit and finance (including his experience as a Certified Public Accountant for Ernst & Young and KPMG Peat Marwick), Mr. Sokolow serves as the Chair of the Company's Audit Committee and is the only current director of the Company who qualifies as an "audit committee financial expert." The Board believes that the failure to re-elect Mr. Sokolow will diminish the capability and effectiveness of the Board, and cause the Board to operate without the benefit of an "audit committee financial expert" unless or until another individual with similar qualification is identified.

    We urge stockholders to follow the Board's recommendation and vote "FOR" all the proposals in the proxy statement, including the re-election of Ms. Beidler-D'Aguilar, Mr. Butler and Mr. Sokolow. If you previously voted "against" or withheld your vote any proposal, you may change that vote simply by voting again TODAY. Only your latest-dated vote will count!

    Your vote is important, please vote your shares today.

    • By Internet: Go to www.proxyvote.com and follow the instructions (have your proxy card available).
    • By Telephone: Call 1-800-690-6903 and follow the voice prompts (have your proxy card available).
    • By Mail: If shareholders have received a proxy card, shareholders should mark their vote, sign their name exactly as it appears on the proxy card, date the card and return it in the envelope provided.

    About Consolidated Water Co. Ltd.

    Consolidated Water Co. Ltd. develops and operates advanced water supply and treatment plants and water distribution systems. The Company designs, constructs and operates seawater desalination facilities in the Cayman Islands, The Bahamas and the British Virgin Islands, and designs, constructs and operates water treatment and reuse facilities in the United States. The Company recently entered the U.S. desalination market with a contract to design, constructs, operate and maintain a seawater desalination plant in Hawaii.

    The Company also manufactures and services a wide range of products and provides design, engineering, management, operating and other services applicable to commercial and municipal water production, supply and treatment, and industrial water and wastewater treatment. For more information, visit cwco.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "intend", "expect", "should", "will" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to (i) continued acceptance of the Company's products and services in the marketplace; (ii) changes in its relationships with the governments of the jurisdictions in which it operates; (iii) the outcome of its negotiations with the Cayman government regarding a new retail license agreement; (iv) the collection of its delinquent accounts receivable in The Bahamas; and (v) various other risks, as detailed in the Company's periodic report filings with the SEC. For more information about risks and uncertainties associated with the Company's business, please refer to the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections of the Company's SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q, copies of which may be obtained by contacting the Company's Secretary at the Company's executive offices or at the "Investors – SEC Filings" page of the Company's website at http://ir.cwco.com/docs. Except as otherwise required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Important Shareholder Information

    The Company filed the Proxy Statement and a proxy card on April 18, 2024 with the SEC in connection with its solicitation of proxies for the 2024 Annual General Meeting of Shareholders. THE COMPANY'S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, THE ACCOMPANYING PROXY CARD, AND ANY AMENDMENTS AND SUPPLEMENTS TO THESE DOCUMENTS WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain the Proxy Statement, any amendments or supplements to the Proxy Statement, and other documents, as and when they become available, without charge from the SEC's website at www.sec.gov.

    Participant Information

    The Company, its directors, director nominees, certain of its officers, and other employees are or will be "participants" (as defined in Section 14(a) of the U.S. Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company's shareholders in connection with the matters to be considered at the 2024 Annual General Meeting of Shareholders. The identity, their direct or indirect interests (by security holdings or otherwise), and other information relating to the participants is available in the Proxy Statement filed with the SEC on April 18, 2024, in the section titled "Security Ownership of Certain Beneficial Owners and Management and Related Shareholders Matters" (beginning on page 17). To the extent the holdings by the "participants" in the solicitation reported in the Proxy Statement have changed, such changes have been or will be reflected on "Statements of Change in Ownership" on Forms 3, 4 or 5 filed with the SEC (where applicable). All these documents are or will be available free of charge at the SEC's website at www.sec.gov.

    Company Contact:

    David W. Sasnett

    Executive Vice President and CFO

    Tel (954) 509-8200

    Email Contact

    Investor Relations Contact:

    Ron Both or Grant Stude

    CMA Investor Relations

    Tel (949) 432-7566

    Email Contact

    Media Contact:

    Tim Randall

    CMA Media Relations

    Tel (949) 432-7572

    Email Contact



    Primary Logo

    Get the next $CWCO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CWCO
    $SKYX
    $VVOS

    CompanyDatePrice TargetRatingAnalyst
    SKYX Platforms Corp.
    $SKYX
    9/10/2024$2.00Buy
    ROTH MKM
    SKYX Platforms Corp.
    $SKYX
    4/29/2024$5.00Outperform
    Noble Capital Markets
    Consolidated Water Co. Ltd.
    $CWCO
    8/14/2023$24.00 → $28.00Neutral → Buy
    Janney
    Consolidated Water Co. Ltd.
    $CWCO
    7/6/2023Buy → Neutral
    Janney
    Consolidated Water Co. Ltd.
    $CWCO
    6/7/2023$24.00Neutral → Buy
    Janney
    Consolidated Water Co. Ltd.
    $CWCO
    5/17/2023$19.00Buy → Neutral
    Janney
    Consolidated Water Co. Ltd.
    $CWCO
    11/16/2022$20.00Neutral → Buy
    Janney
    Consolidated Water Co. Ltd.
    $CWCO
    9/14/2022Buy → Neutral
    Janney
    More analyst ratings

    $CWCO
    $SKYX
    $VVOS
    SEC Filings

    View All

    Vivos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    9/17/25 8:41:12 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    9/12/25 4:52:50 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Vivos Therapeutics Inc.

    424B5 - Vivos Therapeutics, Inc. (0001716166) (Filer)

    9/12/25 4:50:44 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $CWCO
    $SKYX
    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CWCO
    $SKYX
    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Co-Chief Executive Officer Sokolow Leonard J covered exercise/tax liability with 19,675 shares, decreasing direct ownership by 3% to 699,220 units (SEC Form 4)

    4 - SKYX Platforms Corp. (0001598981) (Issuer)

    9/12/25 6:46:26 PM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Director Whittaker Raymond sold $158,579 worth of shares (4,755 units at $33.35), decreasing direct ownership by 83% to 1,000 units (SEC Form 4)

    4 - Consolidated Water Co. Ltd. (0000928340) (Issuer)

    8/25/25 4:10:07 PM ET
    $CWCO
    Water Supply
    Utilities

    SEC Form 4 filed by Chief Operations Officer Barron Patricia Ann

    4 - SKYX Platforms Corp. (0001598981) (Issuer)

    8/18/25 5:00:19 PM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

    LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from OSA. Results from a multicenter clinical trial, now published in the European Journal of Pediatrics, represent a significant milestone in the fight against one of the m

    9/17/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SKYX Successfully Demonstrated Its Technologies During a Marriott SpringHill Suites Hotel Renovation as It Continues to Grow Its Market Penetration in the U.S. and Canada

    SKYX's Marriott Renovation Demonstration Validated the Significant Safety, Simplicity, Time Savings and Cost Savings Provided by SKYX's Technologies During a Renovation Process The Marriott Renovation Demo Incorporated SKYX's Advanced and Smart Plug & Play Technologies, Including Ceiling lighting, Recessed Lights, Down Lights, Wall Lights, EXIT and Emergency Lights, Plug-In LED Backlight Mirrors, Among Others SKYX Expects Its Technologies to Be Utilized and Included in Additional Marriot Renovations as well as in Additional Hotel Brands Major Hotel Chains Commonly Require Its Hotels to Conduct a Full Renovation Every 7 Years MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SKYX Pl

    9/3/25 10:14:28 AM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Consolidated Water Declares Fourth Quarter Cash Dividend

    GEORGE TOWN, Cayman Islands, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, today announced that its board of directors has approved a quarterly cash dividend of $0.14 per share for the fourth quarter of 2025. The cash dividend is payable on October 31, 2025 to shareholders of record at the close of business on October 1, 2025. About Consolidated Water Co. Ltd.Consolidated Water Co. Ltd. develops and operates advanced water supply and treatment plants and water distribution systems. The company designs, constructs and operates seawater desalina

    8/28/25 8:31:00 AM ET
    $CWCO
    Water Supply
    Utilities

    $CWCO
    $SKYX
    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on SKYX Platforms with a new price target

    ROTH MKM initiated coverage of SKYX Platforms with a rating of Buy and set a new price target of $2.00

    9/10/24 8:00:14 AM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Noble Capital Markets initiated coverage on SKYX Platforms with a new price target

    Noble Capital Markets initiated coverage of SKYX Platforms with a rating of Outperform and set a new price target of $5.00

    4/29/24 8:21:59 AM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Consolidated Water upgraded by Janney with a new price target

    Janney upgraded Consolidated Water from Neutral to Buy and set a new price target of $28.00 from $24.00 previously

    8/14/23 7:21:04 AM ET
    $CWCO
    Water Supply
    Utilities

    $CWCO
    $SKYX
    $VVOS
    Leadership Updates

    Live Leadership Updates

    View All

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Former Amazon E-Commerce Director Huey Long Joins SKYX to Lead Its E-Commerce Platform, Expanding SKYX's Market Penetration Across Its 60 Lighting and Home Décor Websites Among Other E-Commerce Leading Channels

    Mr. Long's Proven Track Record in Driving E-Commerce Growth and Innovation Includes Leadership Roles at Walmart, Ashley Furniture, and Amazon Mr. Long will Collaborate with the Existing E-commerce Management Team and Founders to Expand SKYX ‘s Sales and Market Penetration of Its Disruptive Advance and Smart Home Plug & Play Technologies in the U.S. and Canadian Markets MIAMI, March 03, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ:SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive advanced and smart home platform technology company for homes and buildings, with more than 97 issued and pending patents globally and a portfolio of over 60 lighting and ho

    3/3/25 9:20:00 AM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Former Home Depot Lighting Head and Industry Veteran Greg St. John Joins SKYX as President of Lighting, Fans, and Smart Home Products

    MIAMI, Feb. 11, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ:SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and over 60 lighting and home décor websites with a mission to make homes and buildings become smart, safe, and advanced as the new standard announced today that Greg St. John, former head of Home Depot's indoor lighting category and former CEO of world leading lighting companies such as Eglo, and Cordelia Lighting, has joined SKYX as President of Lighting Fans and Smart Products. In his new position, St. John will lead SKYX's growing penetration in lighting, fans,

    2/11/25 8:30:00 AM ET
    $SKYX
    Building Products
    Consumer Discretionary

    $CWCO
    $SKYX
    $VVOS
    Financials

    Live finance-specific insights

    View All

    Consolidated Water Declares Fourth Quarter Cash Dividend

    GEORGE TOWN, Cayman Islands, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, today announced that its board of directors has approved a quarterly cash dividend of $0.14 per share for the fourth quarter of 2025. The cash dividend is payable on October 31, 2025 to shareholders of record at the close of business on October 1, 2025. About Consolidated Water Co. Ltd.Consolidated Water Co. Ltd. develops and operates advanced water supply and treatment plants and water distribution systems. The company designs, constructs and operates seawater desalina

    8/28/25 8:31:00 AM ET
    $CWCO
    Water Supply
    Utilities

    Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported

    8/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

    LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today announced it plans to release its second quarter 2025 financial results after market close today, Tuesday, August 19, 2025. The Company will conduct a conference call at 5:00 pm (Eastern Time) on August 19, 2025, to review the results and provide an overview of the C

    8/19/25 8:30:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $CWCO
    $SKYX
    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by SKYX Platforms Corp.

    SC 13D/A - SKYX Platforms Corp. (0001598981) (Subject)

    11/22/24 5:00:10 PM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:05:24 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care